ARTELO BIOSCIENCES, INC. Increase (Decrease) in Accounts Payable, Related Parties
ARTELO BIOSCIENCES, INC. (ARTL) reported Increase (Decrease) in Accounts Payable, Related Parties of -$234.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties · last filed 2026-08-12
- ARTELO BIOSCIENCES, INC. increase (decrease) in accounts payable, related parties for the quarter ending 2026-06-30 was -$357.00K, a 17950.00% decline year-over-year.
- ARTELO BIOSCIENCES, INC. increase (decrease) in accounts payable, related parties for the quarter ending 2026-03-31 was $123.00K.
- ARTELO BIOSCIENCES, INC. increase (decrease) in accounts payable, related parties for the quarter ending 2025-12-31 was $312.00K, a 1100.00% increase year-over-year.
- ARTELO BIOSCIENCES, INC. increase (decrease) in accounts payable, related parties for the quarter ending 2025-09-30 was $7.00K.
- ARTELO BIOSCIENCES, INC. increase (decrease) in accounts payable, related parties for fiscal 2022 was $33.00K.
- ARTELO BIOSCIENCES, INC. increase (decrease) in accounts payable, related parties for fiscal 2021 was $0.00.
- ARTELO BIOSCIENCES, INC. increase (decrease) in accounts payable, related parties for fiscal 2020 was $0.00.
| Period end | Increase (Decrease) in Accounts Payable, Related Parties 3 month | Increase (Decrease) in Accounts Payable, Related Parties 4 month | Increase (Decrease) in Accounts Payable, Related Parties 6 month | Increase (Decrease) in Accounts Payable, Related Parties 9 month | Increase (Decrease) in Accounts Payable, Related Parties 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$357.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$234.00K 10-Q · filed 2026-08-12 | $78.00K derived: sum of 3 quarters · filed 2026-08-12 | $85.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $123.00K 10-Q · filed 2026-05-14 | $435.00K derived: sum of 2 quarters · filed 2026-05-14 | $442.00K derived: sum of 3 quarters · filed 2026-05-14 | $444.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $312.00K derived: 8-K 12 month − 10-Q 9 month · filed 2026-03-17 | $319.00K derived: sum of 2 quarters · filed 2026-03-17 | $321.00K derived: sum of 3 quarters · filed 2026-08-12 | $283.00K 8-K · filed 2026-03-17 | |
| 2025-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $9.00K derived: sum of 2 quarters · filed 2026-08-12 | -$29.00K 10-Q · filed 2025-11-12 | -$3.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$36.00K 10-Q · filed 2026-08-12 | -$10.00K derived: sum of 3 quarters · filed 2026-08-12 | -$19.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$38.00K 10-Q · filed 2026-05-14 | -$12.00K derived: sum of 2 quarters · filed 2026-05-14 | -$21.00K derived: sum of 3 quarters · filed 2026-05-14 | -$60.00K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $26.00K derived: 8-K 12 month − 10-Q 9 month · filed 2026-03-17 | $17.00K derived: sum of 2 quarters · filed 2026-03-17 | -$22.00K derived: sum of 3 quarters · filed 2026-03-17 | $31.00K 8-K · filed 2026-03-17 | |
| 2024-09-30 | -$9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$48.00K derived: sum of 2 quarters · filed 2025-11-12 | $5.00K 10-Q · filed 2025-11-12 | -$13.00K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$39.00K derived: 10-Q 6 month − 8-K 3 month · filed 2025-08-13 | $14.00K 10-Q · filed 2025-08-13 | -$4.00K derived: sum of 3 quarters · filed 2025-08-13 | $0.00 derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $53.00K 8-K · filed 2025-07-11 | $35.00K derived: sum of 2 quarters · filed 2025-07-11 | $39.00K derived: sum of 3 quarters · filed 2025-07-11 | -$4.00K derived: sum of 4 quarters · filed 2025-07-11 | |
| 2023-12-31 | -$18.00K derived: 8-K 12 month − 10-Q 9 month · filed 2025-07-11 | -$14.00K derived: sum of 2 quarters · filed 2025-07-11 | -$57.00K derived: sum of 3 quarters · filed 2025-07-11 | -$23.00K 8-K · filed 2025-07-11 | |
| 2023-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$39.00K derived: sum of 2 quarters · filed 2024-11-12 | -$5.00K 10-Q · filed 2024-11-12 | $22.00K derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$9.00K 10-Q · filed 2024-08-13 | $18.00K derived: sum of 3 quarters · filed 2024-08-13 | -$5.00K derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $34.00K 10-Q · filed 2024-05-13 | $61.00K derived: sum of 2 quarters · filed 2024-05-13 | $38.00K derived: sum of 3 quarters · filed 2024-05-13 | $44.00K derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $4.00K derived: sum of 2 quarters · filed 2024-03-25 | $10.00K derived: sum of 3 quarters · filed 2024-03-25 | $33.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | -$23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$17.00K derived: sum of 2 quarters · filed 2023-11-13 | $6.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $29.00K 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $23.00K 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | -$7.00K 10-K · filed 2023-03-31 | ||||
| 2021-08-31 | $0.00 10-K · filed 2023-03-31 | ||||
| 2020-12-31 | $0.00 10-KT · filed 2022-03-21 | ||||
| 2020-08-31 | $0.00 10-KT · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |